GSK (GLAXF) Additional Paid-In Capital: $4,676 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLAXF GSK PLC GLAXF
73 GF Score
Price $25.50
GF Value $21.89
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK Additional Paid-In Capital?

GSK GLAXF +0.59% 73 Additional Paid-In Capital is $4,676 Mil as of Jun. 2026. GuruFocus rates GLAXF with a GF Score™ of 73/100 and a GF Value™ of $21.89 (Modestly Overvalued). The stock has 1 warning sign investors should review.


GSK's quarterly additional paid-in capital declined from Dec. 2025 ($4,683 Mil) to Mar. 2026 ($4,675 Mil) but then increased from Mar. 2026 ($4,675 Mil) to Jun. 2026 ($4,676 Mil).

GSK's annual additional paid-in capital increased from Dec. 2023 ($4,368 Mil) to Dec. 2024 ($4,391 Mil) and increased from Dec. 2024 ($4,391 Mil) to Dec. 2025 ($4,683 Mil).

GSK Additional Paid-In Capital Related Terms

GSK Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for GSK's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Additional Paid-In Capital Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,389.63 4,190.01 4,368.35 4,390.65 4,682.73

GSK Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,729.99 4,710.81 4,682.73 4,674.67 4,676.00
GLAXF
73GF Score
GSK PLC GLAXF
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $4,676 Mil mean?
GSK (GLAXF) has a Additional Paid-In Capital of $4,676 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on GSK and its competitors.
Is GSK's Additional Paid-In Capital too high?
GSK's current Additional Paid-In Capital is $4,676 Mil. Overall, GSK has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Additional Paid-In Capital compare to LLY and JNJ?
GSK's Additional Paid-In Capital of $4,676 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Drug Manufacturers company?
A good Additional Paid-In Capital depends on the Drug Manufacturers industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on GSK and its competitors. GSK's current Additional Paid-In Capital is $4,676 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.89, compared to a current price of $25.50 — trading 16.5% above its estimated fair value. The current Additional Paid-In Capital is $4,676 Mil. GSK's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For GSK (GLAXF), the current Additional Paid-In Capital is $4,676 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (GLAXF) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of $25.50 is trading 16.5% above its estimated GF Value™ of $21.89. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for GLAXF:

  • Additional Paid-In Capital: $4,676 Mil
  • GF Value™: $21.89 vs. price of $25.50 (16.5% above fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score

Get the complete analysis for GLAXF

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.50
Price
$21.89
GF Value